Biomarin Pharmaceutical reported $116.96M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
Acorda Therapeutics ACOR:US $ 5.97M 1.77M
Alnylam Pharmaceuticals ALNY:US $ 35.63M 2.04M
Amgen AMGN:US $ 1561M 157M
Bayer BAYN:GR € 5176M 1491M
Biogen BIIB:US $ 753.9M 93.8M
Biomarin Pharmaceutical BMRN:US $ 116.96M 2.78M
Gilead Sciences GILD:US $ 1424M 1203M
Insmed INSM:US $ 12.19M 1.1M
Intercept Pharmaceuticals ICPT:US $ 0.76M 0.26M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
Moderna Inc MRNA:US 1.02B 65M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Ptc Therapeutics PTCT:US $ 10.14M 0.81M
Puma Biotechnology PBYI:US $ 10.84M 1.05M
Regeneron Pharmaceuticals REGN:US $ 404.9M 577.7M
Sarepta Therapeutics SRPT:US $ 31.44M 0.3M
Seattle Genetics SGEN:US $ 87.63M 0.94M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
United Therapeutics UTHR:US $ 25.9M 8.7M
Vertex Pharmaceuticals VRTX:US $ 245.8M 1.59M
YTE INCY:US $ 37.21M 1.36M